TY - JOUR
T1 - New insights in mite immunotherapy - Sublingual tablets
AU - Creticos, Peter Socrates
N1 - Funding Information:
Disclosures: P.S.C. has received research grants from ALK, Stallergenes-Greer, Greer Labs, Inflammax, and Regeneron. He serves as a consultant for Biomay, HAL-Allergy, ITI, and Regeneron, and receives royalties from UpToDate as a section editor and author.
Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Purpose of reviewSublingual tablet immunotherapy has been demonstrated to be effective for allergies induced by exposure to grass, ragweed, specific trees (Japanese Cedar; birch homologous tree mix), and house dust mites (HDM). This review provides both an overview of the evidence-based clinical studies that address the use of the HDM SLIT-tablet for the treatment of HDM-induced allergic rhinitis/conjunctivitis and its appropriate use in carefully selected asthmatic patients and provides the clinician with practical management considerations.Recent findingsSolid evidence-based clinical studies have shown that the HDM SLIT-tablet is both well tolerated in patients with mild-to-moderate asthma and has demonstrated a meaningful improvement in exacerbations, need for rescue medication, quality of life, and asthma control.SummaryThe HDM SLIT-tablet provides the allergy specialist with a well-tolerated treatment that has established superior safety to subcutaneous injection therapy, which can be administered easily as a sublingual dissolvable tablet, and which provides the opportunity to address one of the more difficult aspects in the management of an inducer of perennial allergic disease - that of persistent airway inflammation and allergic asthma.
AB - Purpose of reviewSublingual tablet immunotherapy has been demonstrated to be effective for allergies induced by exposure to grass, ragweed, specific trees (Japanese Cedar; birch homologous tree mix), and house dust mites (HDM). This review provides both an overview of the evidence-based clinical studies that address the use of the HDM SLIT-tablet for the treatment of HDM-induced allergic rhinitis/conjunctivitis and its appropriate use in carefully selected asthmatic patients and provides the clinician with practical management considerations.Recent findingsSolid evidence-based clinical studies have shown that the HDM SLIT-tablet is both well tolerated in patients with mild-to-moderate asthma and has demonstrated a meaningful improvement in exacerbations, need for rescue medication, quality of life, and asthma control.SummaryThe HDM SLIT-tablet provides the allergy specialist with a well-tolerated treatment that has established superior safety to subcutaneous injection therapy, which can be administered easily as a sublingual dissolvable tablet, and which provides the opportunity to address one of the more difficult aspects in the management of an inducer of perennial allergic disease - that of persistent airway inflammation and allergic asthma.
KW - asthma
KW - house dust mite SLIT-tablets
KW - sublingual immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85121402929&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121402929&partnerID=8YFLogxK
U2 - 10.1097/ACI.0000000000000785
DO - 10.1097/ACI.0000000000000785
M3 - Review article
C2 - 34494616
AN - SCOPUS:85121402929
SN - 1528-4050
VL - 21
SP - 602
EP - 610
JO - Current opinion in allergy and clinical immunology
JF - Current opinion in allergy and clinical immunology
IS - 6
ER -